Wnt5a expression in canine osteosarcoma

N. Szigetvari, Denise Imai, C. M. Piskun, L. C.S. Rodrigues, E. Chon, T. J. Stein

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Osteosarcoma is the most common primary malignancy of bone in dogs and is associated with poor long-term outcomes due to its highly metastatic nature. A better understanding of the signalling pathways and proteins involved with osteosarcoma pathogenesis may aid in improved outcomes through the use of targeted therapies. The Wnt5a protein, a ligand for the non-canonical Wnt signalling pathway, is implicated in mediating the aggressiveness of cancer cell lines, including those of human osteosarcoma origin. Given the close relationship between human and canine osteosarcoma, the primary goal of this study was to characterize Wnt5a expression in canine osteosarcoma. Second, if Wnt5a expression was present in canine osteosarcoma, the study aimed to determine any potential association with clinical outcome and clinical variables in similarly treated osteosarcoma-bearing dogs. Wnt5a expression was present in 26 of the 48 (54%) cases of canine osteosarcoma. Wnt5a expression was not associated with progression-free survival (P = 0.4) or overall survival (P = 0.1).

Original languageEnglish (US)
Pages (from-to)225-235
Number of pages11
JournalVeterinary and Comparative Oncology
Volume14
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

osteosarcoma
Osteosarcoma
Canidae
dogs
Dogs
Wnt Signaling Pathway
Disease-Free Survival
aggression
Neoplasms
pathogenesis
proteins
cell lines
bones
Ligands
Bone and Bones
Cell Line
therapeutics
Survival

Keywords

  • cell signalling
  • comparative oncology
  • oncology
  • small animal
  • tumour biology

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Szigetvari, N., Imai, D., Piskun, C. M., Rodrigues, L. C. S., Chon, E., & Stein, T. J. (2016). Wnt5a expression in canine osteosarcoma. Veterinary and Comparative Oncology, 14(3), 225-235. https://doi.org/10.1111/vco.12073

Wnt5a expression in canine osteosarcoma. / Szigetvari, N.; Imai, Denise; Piskun, C. M.; Rodrigues, L. C.S.; Chon, E.; Stein, T. J.

In: Veterinary and Comparative Oncology, Vol. 14, No. 3, 01.09.2016, p. 225-235.

Research output: Contribution to journalArticle

Szigetvari, N, Imai, D, Piskun, CM, Rodrigues, LCS, Chon, E & Stein, TJ 2016, 'Wnt5a expression in canine osteosarcoma', Veterinary and Comparative Oncology, vol. 14, no. 3, pp. 225-235. https://doi.org/10.1111/vco.12073
Szigetvari N, Imai D, Piskun CM, Rodrigues LCS, Chon E, Stein TJ. Wnt5a expression in canine osteosarcoma. Veterinary and Comparative Oncology. 2016 Sep 1;14(3):225-235. https://doi.org/10.1111/vco.12073
Szigetvari, N. ; Imai, Denise ; Piskun, C. M. ; Rodrigues, L. C.S. ; Chon, E. ; Stein, T. J. / Wnt5a expression in canine osteosarcoma. In: Veterinary and Comparative Oncology. 2016 ; Vol. 14, No. 3. pp. 225-235.
@article{a7f8488e754d4caa9d5e25df340cc35f,
title = "Wnt5a expression in canine osteosarcoma",
abstract = "Osteosarcoma is the most common primary malignancy of bone in dogs and is associated with poor long-term outcomes due to its highly metastatic nature. A better understanding of the signalling pathways and proteins involved with osteosarcoma pathogenesis may aid in improved outcomes through the use of targeted therapies. The Wnt5a protein, a ligand for the non-canonical Wnt signalling pathway, is implicated in mediating the aggressiveness of cancer cell lines, including those of human osteosarcoma origin. Given the close relationship between human and canine osteosarcoma, the primary goal of this study was to characterize Wnt5a expression in canine osteosarcoma. Second, if Wnt5a expression was present in canine osteosarcoma, the study aimed to determine any potential association with clinical outcome and clinical variables in similarly treated osteosarcoma-bearing dogs. Wnt5a expression was present in 26 of the 48 (54{\%}) cases of canine osteosarcoma. Wnt5a expression was not associated with progression-free survival (P = 0.4) or overall survival (P = 0.1).",
keywords = "cell signalling, comparative oncology, oncology, small animal, tumour biology",
author = "N. Szigetvari and Denise Imai and Piskun, {C. M.} and Rodrigues, {L. C.S.} and E. Chon and Stein, {T. J.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/vco.12073",
language = "English (US)",
volume = "14",
pages = "225--235",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Wnt5a expression in canine osteosarcoma

AU - Szigetvari, N.

AU - Imai, Denise

AU - Piskun, C. M.

AU - Rodrigues, L. C.S.

AU - Chon, E.

AU - Stein, T. J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Osteosarcoma is the most common primary malignancy of bone in dogs and is associated with poor long-term outcomes due to its highly metastatic nature. A better understanding of the signalling pathways and proteins involved with osteosarcoma pathogenesis may aid in improved outcomes through the use of targeted therapies. The Wnt5a protein, a ligand for the non-canonical Wnt signalling pathway, is implicated in mediating the aggressiveness of cancer cell lines, including those of human osteosarcoma origin. Given the close relationship between human and canine osteosarcoma, the primary goal of this study was to characterize Wnt5a expression in canine osteosarcoma. Second, if Wnt5a expression was present in canine osteosarcoma, the study aimed to determine any potential association with clinical outcome and clinical variables in similarly treated osteosarcoma-bearing dogs. Wnt5a expression was present in 26 of the 48 (54%) cases of canine osteosarcoma. Wnt5a expression was not associated with progression-free survival (P = 0.4) or overall survival (P = 0.1).

AB - Osteosarcoma is the most common primary malignancy of bone in dogs and is associated with poor long-term outcomes due to its highly metastatic nature. A better understanding of the signalling pathways and proteins involved with osteosarcoma pathogenesis may aid in improved outcomes through the use of targeted therapies. The Wnt5a protein, a ligand for the non-canonical Wnt signalling pathway, is implicated in mediating the aggressiveness of cancer cell lines, including those of human osteosarcoma origin. Given the close relationship between human and canine osteosarcoma, the primary goal of this study was to characterize Wnt5a expression in canine osteosarcoma. Second, if Wnt5a expression was present in canine osteosarcoma, the study aimed to determine any potential association with clinical outcome and clinical variables in similarly treated osteosarcoma-bearing dogs. Wnt5a expression was present in 26 of the 48 (54%) cases of canine osteosarcoma. Wnt5a expression was not associated with progression-free survival (P = 0.4) or overall survival (P = 0.1).

KW - cell signalling

KW - comparative oncology

KW - oncology

KW - small animal

KW - tumour biology

UR - http://www.scopus.com/inward/record.url?scp=84886170577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886170577&partnerID=8YFLogxK

U2 - 10.1111/vco.12073

DO - 10.1111/vco.12073

M3 - Article

AN - SCOPUS:84886170577

VL - 14

SP - 225

EP - 235

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 3

ER -